Johnson & Johnson reports Q3 2026 results, raises 2026 guidance
Johnson & Johnson reported Q3 2026 sales of $25.4 billion, up 5.9% reported and 6.1% adjusted operational, with Innovative Medicine growing 7.9% operationally and MedTech 2.5%. GAAP EPS fell to $0.09 from $2.12, driven by a one-time special charge tied to the proposed talc litigation resolution plus the Firefly Bio acquisition and Sail Biomedicines collaboration; adjusted EPS was $2.59, down 7.5% year-over-year. The company raised FY2026 guidance, lifting estimated reported sales to $101.2 billion at the midpoint (+7.4%) and adjusted EPS guidance by $0.06 to $11.10 at the midpoint.
Key figures
- Eps
- 0.09
- Revenue
- 25399000000
- Guidance
- FY2026 reported sales $101.0B-$101.4B ($101.2B midpoint, +7.4%); adjusted EPS raised by $0.06 to $11.05-$11.15 ($11.10 midpoint)
- Revenue Yoy
- 5.9%
- Adjusted eps
- 2.59
- Net earnings
- 210000000
- Medtech sales
- 8642000000
- Free cash flow
- ~$15,100M YTD
- Adjusted eps yoy
- -7.5%
- Litigation charge q3
- 5519000000
- Adjusted net earnings
- 6339000000
- Operational sales growth
- 6.0%
- Innovative medicine sales
- 16757000000
- Adjusted operational sales growth
- 6.1%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.